Skip to main content

Henry Skinner, Satish Jindal,Patrick Carroll, Paulette Dillon, Mark Lotz, Jack Wyszomierski, James Simpkins, Neil Hocking, Steven Deitcher


Henry Skinner has been promoted to CEO from chief business officer of NeoGenesis Pharmaceuticals. He will also serve on the company’s board of directors. Skinner replaces Satish Jindal, who stays on as NeoGenesis’ CSO and chairman of its board. Before joining NeoGenesis last fall, Skinner was senior director for technology acquisitions and operations at Pfizer, working for its Pharmacia unit. Skinner holds a PhD in microbiology and a master’s degree in biochemistry from the University of Illinois at Urbana-Champaign, as well as bachelor’s and master’s degrees in biology/biotechnology from Worcester Polytechnic Institute.

Patrick Carroll has become chief business officer of BioTrove. He joins the shop from Applied Biosystems, where he was senior vice president of worldwide sales. He holds MS and BA degrees in biological sciences from the University of Delaware and an MBA in marketing from Loyola College.

Paulette Dillon has been appointed chief business officer of Celera Genomics, the company said this week. She comes to Celera from Exelixis Pharmaceuticals, where she was vice president for marketing and business development.

Mark Lotz has become vice president for regulatory affairs of MediciNova. Prior to joining the company, he held positions at Isis Pharmaceuticals, Amylin Pharmaceuticals, and Abbott Laboratories. Lotz has a BS in pharmacy from the St. Louis College of Pharmacy.

Beyond Genomics has appointed Stelios Papadopoulos to the board of directors. He is a vice chairman of SG Cowen Securities and covers biotechnology and the pharmaceutical industry as an investment banker. Papadopoulos holds a PhD in biophysics and an MBA in finance from New York University.

Jack Wyszomierski has been appointed to the board of directors of Exelixis, the company said this week. He was executive vice president and CFO of Schering-Plough until last year. Wyszomierski holds an MS in industrial administration and a BS in administration, management science, and economics from Carnegie Mellon University.

GeneLink has appointed James Simpkins to head its medical advisory board. The company also appointed Donald Cannon to its board of directors.

Simpkins currently works at the University of North Texas Health Science Center, where he is the chair of the Department of Pharmacology and Neuroscience, and director of the Institute for Aging and Alzheimer’s Disease Research. He received his BS and MS from the University of Toledo, and received a PhD in physiology from Michigan State University.

Cannon, a former Quest Diagnostics executive, received his AB in chemistry and his MA in medical sciences from Harvard College, and a PhD in biochemistry from Boston University.

Neil Hocking has been named executive director for business development in Europe at Gene Logic’s new UK-based subsidiary [see SNIPPETS, page 8]. Previously, he had worked for Sanyo, MDL, and Celera Genomics.

Steven Deitcher has become vice president for medical affairs at Nuvelo.


Filed under

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.